News
Visit of Shanghai Pharmaceuticals and Shanghai Healthcare Capital for technology exchange and collaboration
4 Aug, 2022
Arranged by Hong Kong Science & Technology Parks Corporation and HKBU's Institute for Innovation, Translation and Policy Research, a delegation led by Mr. Zuo Min and a group of senior management from Shanghai Pharmaceuticals Holding Company Limited (SPH) and Shanghai Healthcare Capital (SHC) visited HKBU. They are welcomed by Prof. Alexander Wai, President and Vice-Chancellor, Prof. Rick WK Wong, Interim Provost, Prof. Guo Yike, Vice-President (Research and Development), Professor Terence Lau, Interim Chief Innovation Officer, and Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development), etc.
The meeting covered an overview on SPH’s traditional Chinese medicine (TCM) development and innovation strategy, the latest Chinese medicine technology development by HKBU and has initiated further collaboration possibility on novel TCM discovery, including SPH's support for commercialisation and technology innovation, the opportunities for incubation and translation of technology project to apply in the local and the Greater Bay Area.
Prof. Zhang Ge, Associate Dean (Research), School of Chinese Medicine, gave a presentation on “From Molecular Target to Aptamer Drug Discovery towards US-FDA Orphan Drug Designation” while Prof. Wei Jia, Associate Dean (International Collaboration), School of Chinese Medicine, shared the new drug development of Hong Kong Traditional Chinese Medicine Phenome Research Centre.